PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma

Athanassios Argiris, Ann Mellott, Stewart Spies

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Paragangliomas are indolent tumors that arise from the chief cells of the paraganglia in the head and neck, mediastinum, and retroperitoneal regions. Less than 10% of paragangliomas metastasize. Paragangliomas are known to regress slowly and usually partially after radiation therapy, which has been attributed to the development of fibrosis within the abundant vascular elements of the tumor. Positron emission tomography (PET) scanning was used to monitor a 33-year-old woman with recurrent paraganglioma of the carotid body with lung and bone metastases before and after chemotherapy with cyclophosphamide, doxorubicin (Adriamycin), and dacarbazine. The patient derived clinical benefit from chemotherapy, with marked improvement of her systemic and respiratory symptoms, improvement of cancer-related anemia, and normalization of chromogranin A levels. A response was demonstrated on PET scan with decreased [18F] fluoro-2-deoxy-D-glucose uptake after chemotherapy, but no significant changes were detected on serial computed tomography (CT) scans. The patient has remained free of disease progression 24 months after chemotherapy completion. It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas.

Original languageEnglish (US)
Pages (from-to)563-566
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Paraganglioma
Positron-Emission Tomography
Drug Therapy
Doxorubicin
Tomography
Carotid Body Tumor
Chromogranin A
Neoplasms
Dacarbazine
Deoxyglucose
Mediastinum
Physiologic Monitoring
Cyclophosphamide
Blood Vessels
Disease Progression
Anemia
Fibrosis
Neck
Radiotherapy
Head

Keywords

  • Chemotherapy
  • Metastases
  • Paraganglioma
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma. / Argiris, Athanassios; Mellott, Ann; Spies, Stewart.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 6, 12.2003, p. 563-566.

Research output: Contribution to journalArticle

Argiris, Athanassios ; Mellott, Ann ; Spies, Stewart. / PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 6. pp. 563-566.
@article{d8b619f982b3440aaffa73a233ad8671,
title = "PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma",
abstract = "Paragangliomas are indolent tumors that arise from the chief cells of the paraganglia in the head and neck, mediastinum, and retroperitoneal regions. Less than 10{\%} of paragangliomas metastasize. Paragangliomas are known to regress slowly and usually partially after radiation therapy, which has been attributed to the development of fibrosis within the abundant vascular elements of the tumor. Positron emission tomography (PET) scanning was used to monitor a 33-year-old woman with recurrent paraganglioma of the carotid body with lung and bone metastases before and after chemotherapy with cyclophosphamide, doxorubicin (Adriamycin), and dacarbazine. The patient derived clinical benefit from chemotherapy, with marked improvement of her systemic and respiratory symptoms, improvement of cancer-related anemia, and normalization of chromogranin A levels. A response was demonstrated on PET scan with decreased [18F] fluoro-2-deoxy-D-glucose uptake after chemotherapy, but no significant changes were detected on serial computed tomography (CT) scans. The patient has remained free of disease progression 24 months after chemotherapy completion. It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas.",
keywords = "Chemotherapy, Metastases, Paraganglioma, Positron emission tomography",
author = "Athanassios Argiris and Ann Mellott and Stewart Spies",
year = "2003",
month = "12",
doi = "10.1097/01.coc.0000037765.75950.3A",
language = "English (US)",
volume = "26",
pages = "563--566",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - PET Scan Assessment of Chemotherapy Response in Metastatic Paraganglioma

AU - Argiris, Athanassios

AU - Mellott, Ann

AU - Spies, Stewart

PY - 2003/12

Y1 - 2003/12

N2 - Paragangliomas are indolent tumors that arise from the chief cells of the paraganglia in the head and neck, mediastinum, and retroperitoneal regions. Less than 10% of paragangliomas metastasize. Paragangliomas are known to regress slowly and usually partially after radiation therapy, which has been attributed to the development of fibrosis within the abundant vascular elements of the tumor. Positron emission tomography (PET) scanning was used to monitor a 33-year-old woman with recurrent paraganglioma of the carotid body with lung and bone metastases before and after chemotherapy with cyclophosphamide, doxorubicin (Adriamycin), and dacarbazine. The patient derived clinical benefit from chemotherapy, with marked improvement of her systemic and respiratory symptoms, improvement of cancer-related anemia, and normalization of chromogranin A levels. A response was demonstrated on PET scan with decreased [18F] fluoro-2-deoxy-D-glucose uptake after chemotherapy, but no significant changes were detected on serial computed tomography (CT) scans. The patient has remained free of disease progression 24 months after chemotherapy completion. It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas.

AB - Paragangliomas are indolent tumors that arise from the chief cells of the paraganglia in the head and neck, mediastinum, and retroperitoneal regions. Less than 10% of paragangliomas metastasize. Paragangliomas are known to regress slowly and usually partially after radiation therapy, which has been attributed to the development of fibrosis within the abundant vascular elements of the tumor. Positron emission tomography (PET) scanning was used to monitor a 33-year-old woman with recurrent paraganglioma of the carotid body with lung and bone metastases before and after chemotherapy with cyclophosphamide, doxorubicin (Adriamycin), and dacarbazine. The patient derived clinical benefit from chemotherapy, with marked improvement of her systemic and respiratory symptoms, improvement of cancer-related anemia, and normalization of chromogranin A levels. A response was demonstrated on PET scan with decreased [18F] fluoro-2-deoxy-D-glucose uptake after chemotherapy, but no significant changes were detected on serial computed tomography (CT) scans. The patient has remained free of disease progression 24 months after chemotherapy completion. It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas.

KW - Chemotherapy

KW - Metastases

KW - Paraganglioma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0346874287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346874287&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000037765.75950.3A

DO - 10.1097/01.coc.0000037765.75950.3A

M3 - Article

C2 - 14663372

AN - SCOPUS:0346874287

VL - 26

SP - 563

EP - 566

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -